Table S1. Comparing characteristics and outcomes of beta-lactams, beta-lactams combination and vancomycin among patients with ampicillin – susceptible enterococci bloodstream infections.

Characteristics	Anti-enterococcal beta-lactams (*n*=123)	Anti-enterococcal beta-lactams combination (*n*=24)	Vancomycin (*n*=13)	*p* value
Male	76 (61.8)	14 (10)	6 (46.2)	0.557
Age (years), median (IQR)	75 (20)	74 (16)	71 (22)	0.672
ACCI, median (IQR)	5 (3)	6 (3)	6 (2)	0.787
Immunocompromised status	19 (15.4)	2 (8.3)	2 (15.4)	0.719
Time from admission to bacteremia onset (days), median (IQR)	4 (17)	0 (19)	18 (14)	0.169
Hospital acquired bacteremia	68 (55.3)	12 (50)	11 (84.6)	0.089
Intensive – care unit	26 (21.1)	4 (16.7)	5 (38.5)	0.285
Mechanical ventilation	42 (34.1)	8 (33.3)	8 (61.5)	0.155
Septic shock	27 (22.0)	6 (25.0)	4 (30.8)	0.752
PBS, median (IQR)	2 (4)	1.5 (4)	3 (5)	0.242
Sites of infection				
Primary bacteremia	35 (28.5)	7 (29.2)	5 (38.5)	0.753
Intraabdominal infection	28 (22.8)	3 (12.5)	4 (30.8)	0.388
Intravascular catheter infection	18 (14.6)	5 (20.8)	3 (23.1)	0.508
Urinary system infection	19 (15.4)	1 (4.2)	1 (7.7)	0.32
Infective endocarditis	5 (4.1)	7 (29.2)	0	0.001 *
Skin and soft tissue infection	9 (7.3)	0	0	0.368
Bone and joint infection	5 (4.1)	1 (4.2)	0	1.0
Lower respiratory tract infection (Empyema thoracis)	3 (2.4)	0	0	1.0
Reproductive tract infection	1 (0.8)	0	0	1.0
Species				
E. faecalis	107(87)	23 (95.8)	9 (69.2)	0.08
E. faecium	10 (8.1)	0	4 (30.8)	0.011 *
E. gallinarum	2 (1.6)	0	0	1.0
E. hirae	1 (0.8)	0	0	1.0
Enterococcus spp.	3 (2.4)	1 (4.2)	0	1.0
Polymicrobial bacteremia	34 (27.6)	5 (20.8)	2 (15.4)	0.531
Polymicrobial infection	41 (33.3)	5 (20.8)	3 (23.1)	0.395
Time to appropriate therapy (days), median (IQR)	1 (3)	0 (2)	0 (1)	0.021
Switch therapy from IV to oral	20 (16.3)	2 (8.3)	0	0.275
Source control	39 (31.7)	8 (33.3)	3 (23.1)	0.793
Treatment outcomes				
All-cause 30 – day mortality	32 (26.0)	6 (25.0)	8 (61.5)	0.024 *
All-cause in – hospital mortality	50 (40.7)	8 (33.3)	9 (69.2)	0.092
Clinical stability	94 (76.4)	17 (70.8)	3 (23.1)	<0.001 *

Characteristics	Anti-enterococcal beta-lactams (*n*=123)	Anti-enterococcal beta-lactams combination (*n*=24)	Vancomycin (*n*=13)	*p* value
Time to clinical stability (days); median (IQR)	4 (5)	5 (7)	3 (-*)	0.494
Length of stay after infection (days); median (IQR)	18 (22)	22 (31)	15 (17)	0.184
Relapse ASE bacteremia; median (IQR)	6 (4.9)	1 (4.2)	0	1.0
Microbiological clearance within 7 days (N=104)	64 (52)	11 (45.8)	9 (69.2)	0.379
Adverse outcomes				
Vancomycin – resistant enterococci*	3 (2.4)	1 (4.2)	1 (7.7)	0.327
Acute kidney injury	18 (14.6)	6 (25.0)	2 (15.4)	0.439

Abbreviations: ACCI, age-adjusted Charlson Comorbidity Index; IV, intravenous; IQR, interquartile range; PBS, Pitt bacteremia score

* The 25th percentile: 2, the 50th percentile: -